1.60
1.60 (0%)
As of Feb 14, 2025
Lexaria Bioscience Corp. [LEXX]
Source:
Company Overview
Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECHTM drug delivery-enabling platform technology
| Country | United States |
| Headquarters | kelowna |
| Phone Number | 250-765-6424 |
| Industry | manufacturing |
| CEO | Richard Christopher |
| Website | www.cdc.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.2 |
| Operating Profit | $-2.7 |
| Net Income | $-2.7 |
| Net Cash | $1.6 |
Profit Ratios
| Gross Margin | $0.2 |
| Operating Margin | -1,463 |
| Profit as % of Revenues | -6.7% |
| Profit as % of Assets | -29% |
| Profit as % of Stockholder Equity | -28.8% |
Management Effectiveness
| Return on Equity | -28.8% |
| Return on Assets | -27.6% |
| Turnover Ratio | 2% |
| EBITA | $-2.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $9.8 |
| Total Liabilities | $0.4 |
| Operating Cash Flow | $-2.7 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $4.3 |
